小型植入式连续流心室辅助装置在低体重心衰儿童中的前瞻性多中心可行性研究
针对体重8至30 kg的严重收缩性心衰患儿,在7个美国中心开展Jarvik 2015小型植入式连续流左心室辅助装置的可行性研究。7例患儿中位年龄2.2岁、中位体重10 kg,中位支持时间149天,全部达到30天无严重卒中或装置失效的主要可行性终点,其中5例过渡至心脏移植、1例恢复、1例转换为体外装置。
要点
- 7例8至30 kg严重收缩性心衰患儿植入Jarvik 2015后全部存活至30天且无严重卒中或装置失效。
- 中位支持时间149天,5例桥接至移植、1例恢复、1例转换为体外双心室辅助装置。
- 1例在装置支持第53天发生缺血性卒中,另1例因难治性室性心律失常需ECMO支持。
核心结论
- Jarvik 2015左心室辅助装置看来对低体重儿童具有重要前景,可能支持出院;FDA已批准该装置进入22例受试者的关键性试验。
- 由于企业面临财务挑战,该装置能否最终商业化尚不明确。
研究设计与样本
- 由美国国立心肺血液研究所资助的PumpKIN研究,为前瞻性多中心可行性研究,在美国7个中心招募体重8至30 kg、严重收缩性心衰且最佳药物治疗失败、拟行桥接至心脏移植的儿童。
- 排除严重右心衰竭和单心室先天性心脏病患者;主要可行性终点为30天存活且无严重卒中或装置失效。
主要发现
- 7例植入患儿中位年龄2.2岁(范围0.7至7.1岁),中位体重10 kg(范围8.2至20.7 kg);86%为扩张型心肌病,29%为INTERMACS 1级。
- Jarvik 2015中位支持时间149天(范围5至188天),7例全部存活,其中5例至心脏移植、1例至恢复、1例转换为体外装置。
- 1例在装置支持第53天于心肌恢复背景下发生缺血性卒中;1例因难治性室性心律失常需ECMO支持,最终经体外双心室辅助装置支持后接受移植。
- 中位泵速1600 RPM,功率范围1至4 W;中位血浆游离血红蛋白在7、30、90、180天或装置移除时分别为19、30、19、30 mg/dL。
- 所有患者均达到主要可行性终点;患者报告结局显示装置在参与全方位活动方面表现良好。
关键数值与推荐
- 主要可行性终点为30天存活且无严重卒中或非运行性装置失效,7例患儿全部达到。
- 由于制造商财务问题,研究在第八例患者知情同意后暂停;FDA已批准该装置进入22例受试者的关键性试验。
临床怎么用
- 原文未据此给出临床推荐,仅报告该装置在8至30 kg严重收缩性心衰儿童中作为桥接至心脏移植的初步可行性结果。
局限性
- 由于制造商财务问题,研究在第八例患者知情同意后暂停。
- 该装置能否最终商业化尚不明确,原因是开发儿科医疗器械的产业面临财务挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is no FDA-approved left ventricular assist device (LVAD) for smaller children permitting routine hospital discharge. Smaller children supported with LVADs typically remain hospitalized for months awaiting heart transplant-a major burden for families and a challenge for hospitals. We describe the initial outcomes of the Jarvik 2015, a miniaturized implantable continuous flow LVAD, in the NHLBI-funded Pumps for Kids, Infants, and Neonates (PumpKIN) study, for bridge-to-heart transplant. METHODS: Children weighing 8 to 30 kg with severe systolic heart failure and failing optimal medical therapy were recruited at 7 centers in the United States. Patients with severe right heart failure and single-ventricle congenital heart disease were excluded. The primary feasibility endpoint was survival to 30 days without severe stroke or non-operational device failure. RESULTS: Of 7 children implanted, the median age was 2.2 (range 0.7, 7.1) years, median weight 10 (8.2 to 20.7) kilograms; 86% had dilated cardiomyopathy; 29% were INTERMACS profile 1. The median duration of Jarvik 2015 support was 149 (range 5 to 188) days where all 7 children survived including 5 to heart transplant, 1 to recovery, and 1 to conversion to a paracorporeal device. One patient experienced an ischemic stroke on day 53 of device support in the setting of myocardial recovery. One patient required ECMO support for intractable ventricular arrhythmias and was eventually transplanted from paracorporeal biventricular VAD support. The median pump speed was 1600 RPM with power ranging from 1-4 Watts. The median plasma free hemoglobin was 19, 30, 19 and 30 mg/dL at 7, 30, 90 and 180 days or time of explant, respectively. All patients reached the primary feasibility endpoint. Patient-reported outcomes with the device were favorable with respect to participation in a full range of activities. Due to financial issues with the manufacturer, the study was suspended after consent of the eighth patient. CONCLUSION: The Jarvik 2015 LVAD appears to hold important promise as an implantable continuous flow device for smaller children that may support hospital discharge. The FDA has approved the device to proceed to a 22-subject pivotal trial. Whether this device will survive to commercialization remains unclear because of the financial challenges faced by industry seeking to develop pediatric medical devices. (Supported by NIH/NHLBI HHS Contract N268201200001I, clinicaltrials.gov 02954497).
引用
- Almond CS, Davies R, Adachi I, et al. A prospective multicenter feasibility study of a miniaturized implantable continuous flow ventricular assist device in smaller children with heart failure. J Heart Lung Transplant. 2024. PMID: 38713124. doi:10.1016/j.healun.2024.02.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。